Export Ready — 

Tongue Hyperpigmentation Associated with Temozolomide as a Single Agent: Case Report

Bibliographic Details
Main Author: Gil, Lúcia Moreira
Publication Date: 2022
Other Authors: Marques, Joana, Salgado, Duarte
Format: Article
Language: eng
Source: Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
Download full: https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/15987
Summary: Hyperpigmentation of the tongue has been associated with chemotherapy, specifically cytotoxic drugs, but the exact pathophysiological mechanism is still not well understood. We describe a 37-year-old black woman that presented with tongue hyperpigmentation one week after the initiation of chemotherapy with temozolomide as a single agent. No cases of tongue hyperpigmentation associated with temozolomide as a single agent have been reported before. The diagnosis of drug associated pigmentary changes is based on the confirmation the onset of the clinical observations shortly after the initiation of the chemotherapy agent. The tongue hyperpigmentation is usually self-limited. This case constitutes a challenge for healthcare professionals and patients and emphasizes the importance of documenting these cases in order to guide healthcare professionals in managing the expectations of the patients and the potential adverse effects associated with certain drugs.
id RCAP_d43613486cc1aa80f828d6bcba0eea18
oai_identifier_str oai:ojs.www.actamedicaportuguesa.com:article/15987
network_acronym_str RCAP
network_name_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository_id_str https://opendoar.ac.uk/repository/7160
spelling Tongue Hyperpigmentation Associated with Temozolomide as a Single Agent: Case ReportHiperpigmentação da Língua Associada a Temozolomida em Monoterapia: Caso ClínicoHyperpigmentation/chemically inducedTemozolomide/adverse effectsTongue Diseases/chemically inducedDoenças da Língua/induzida quimicamenteHiperpigmentação/induzida quimicamenteTemozolomida/efeitos adversosHyperpigmentation of the tongue has been associated with chemotherapy, specifically cytotoxic drugs, but the exact pathophysiological mechanism is still not well understood. We describe a 37-year-old black woman that presented with tongue hyperpigmentation one week after the initiation of chemotherapy with temozolomide as a single agent. No cases of tongue hyperpigmentation associated with temozolomide as a single agent have been reported before. The diagnosis of drug associated pigmentary changes is based on the confirmation the onset of the clinical observations shortly after the initiation of the chemotherapy agent. The tongue hyperpigmentation is usually self-limited. This case constitutes a challenge for healthcare professionals and patients and emphasizes the importance of documenting these cases in order to guide healthcare professionals in managing the expectations of the patients and the potential adverse effects associated with certain drugs.A hiperpigmentação da língua tem sido associada a quimioterapia, especificamente a fármacos citotóxicos, mas o mecanismo fisiopatológico exato não é conhecido. Apresentamos o caso clínico de uma mulher de raça negra, de 37 anos que apresentou hiperpigmentação da língua uma semana após o início da quimioterapia com temozolomida em monoterapia. Nenhum caso de hiperpigmentação da língua associada à temozolomida em monoterapia foi antes relatado. O diagnóstico de alterações pigmentares associadas ao medicamento é baseado na correlação temporal do início dos achados clínicos com o início do agente quimioterápico. A hiperpigmentação da língua geralmente é autolimitada. Este caso constitui um desafio para os profissionais de saúde e para os doentes e enfatiza a importância de documentar estes casos, a fim de orientar os profissionais de saúde na gestão das expectativas dos doentes e dos potenciais efeitos adversos associados a determinados fármacos.Ordem dos Médicos2022-09-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/15987Acta Médica Portuguesa; Vol. 35 No. 9 (2022): September; 672-674Acta Médica Portuguesa; Vol. 35 N.º 9 (2022): Setembro; 672-6741646-07580870-399Xreponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiainstacron:RCAAPenghttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/15987https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/15987/6575Direitos de Autor (c) 2022 Acta Médica Portuguesainfo:eu-repo/semantics/openAccessGil, Lúcia MoreiraMarques, JoanaSalgado, Duarte2023-01-15T03:00:39Zoai:ojs.www.actamedicaportuguesa.com:article/15987Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireinfo@rcaap.ptopendoar:https://opendoar.ac.uk/repository/71602025-05-28T10:49:01.670498Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiafalse
dc.title.none.fl_str_mv Tongue Hyperpigmentation Associated with Temozolomide as a Single Agent: Case Report
Hiperpigmentação da Língua Associada a Temozolomida em Monoterapia: Caso Clínico
title Tongue Hyperpigmentation Associated with Temozolomide as a Single Agent: Case Report
spellingShingle Tongue Hyperpigmentation Associated with Temozolomide as a Single Agent: Case Report
Gil, Lúcia Moreira
Hyperpigmentation/chemically induced
Temozolomide/adverse effects
Tongue Diseases/chemically induced
Doenças da Língua/induzida quimicamente
Hiperpigmentação/induzida quimicamente
Temozolomida/efeitos adversos
title_short Tongue Hyperpigmentation Associated with Temozolomide as a Single Agent: Case Report
title_full Tongue Hyperpigmentation Associated with Temozolomide as a Single Agent: Case Report
title_fullStr Tongue Hyperpigmentation Associated with Temozolomide as a Single Agent: Case Report
title_full_unstemmed Tongue Hyperpigmentation Associated with Temozolomide as a Single Agent: Case Report
title_sort Tongue Hyperpigmentation Associated with Temozolomide as a Single Agent: Case Report
author Gil, Lúcia Moreira
author_facet Gil, Lúcia Moreira
Marques, Joana
Salgado, Duarte
author_role author
author2 Marques, Joana
Salgado, Duarte
author2_role author
author
dc.contributor.author.fl_str_mv Gil, Lúcia Moreira
Marques, Joana
Salgado, Duarte
dc.subject.por.fl_str_mv Hyperpigmentation/chemically induced
Temozolomide/adverse effects
Tongue Diseases/chemically induced
Doenças da Língua/induzida quimicamente
Hiperpigmentação/induzida quimicamente
Temozolomida/efeitos adversos
topic Hyperpigmentation/chemically induced
Temozolomide/adverse effects
Tongue Diseases/chemically induced
Doenças da Língua/induzida quimicamente
Hiperpigmentação/induzida quimicamente
Temozolomida/efeitos adversos
description Hyperpigmentation of the tongue has been associated with chemotherapy, specifically cytotoxic drugs, but the exact pathophysiological mechanism is still not well understood. We describe a 37-year-old black woman that presented with tongue hyperpigmentation one week after the initiation of chemotherapy with temozolomide as a single agent. No cases of tongue hyperpigmentation associated with temozolomide as a single agent have been reported before. The diagnosis of drug associated pigmentary changes is based on the confirmation the onset of the clinical observations shortly after the initiation of the chemotherapy agent. The tongue hyperpigmentation is usually self-limited. This case constitutes a challenge for healthcare professionals and patients and emphasizes the importance of documenting these cases in order to guide healthcare professionals in managing the expectations of the patients and the potential adverse effects associated with certain drugs.
publishDate 2022
dc.date.none.fl_str_mv 2022-09-01
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/15987
url https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/15987
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/15987
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/15987/6575
dc.rights.driver.fl_str_mv Direitos de Autor (c) 2022 Acta Médica Portuguesa
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Direitos de Autor (c) 2022 Acta Médica Portuguesa
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Ordem dos Médicos
publisher.none.fl_str_mv Ordem dos Médicos
dc.source.none.fl_str_mv Acta Médica Portuguesa; Vol. 35 No. 9 (2022): September; 672-674
Acta Médica Portuguesa; Vol. 35 N.º 9 (2022): Setembro; 672-674
1646-0758
0870-399X
reponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron:RCAAP
instname_str FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron_str RCAAP
institution RCAAP
reponame_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
collection Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository.name.fl_str_mv Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
repository.mail.fl_str_mv info@rcaap.pt
_version_ 1833591268649730048